Zoetis Inc. faced a 5% stock drop following the release of its disappointing Q1 2026 earnings, which missed Wall Street estimates and led to cuts in both revenue and profit forecasts. The revisions stem from decreased demand for its animal healthcare products, including vaccines and medicines for pets and livestock. Analysts have reacted by lowering price targets for the stock, while the company maintains a dividend of $0.53 per share, highlighting its commitment to shareholder value amidst ongoing challenges.
“ZS · is priced at · 174.69 · +8.47%”
“ZS · has stock price · 174.69”
“Zoetis · reported · disappointing Q1 2026 earnings · true”
“Zoetis · cut · revenue and EPS guidance · true”
“Zoetis · declared · $0.53 per share dividend · true”
“Zoetis · is headquartered in · Parsippany, New Jersey · true”
“Zoetis · was incorporated in · 2012 · true”
“Zoetis · employs · 14,500 · true”
“ZTS · is trading at · 288% premium · true”
“Zoetis · is listed on · NYSE · ZTS”
“Kristin C. Peck · is the CEO of · Zoetis, Inc.”
“Zoetis, Inc. · is headquartered in · Parsippany, New Jersey”
